

# Phytopharmaceuticals: An Emerging Field for India's Herbal Tradition

Prof. Dr. Rupali H. Asawale\*, Prof. Pallavi B. Gaikwad

Pharmaceutics Department, Faculty of Pharmacy, RJSPM College of Pharmacy, Dudulgaon, Pune, Maharashtra, India

DOI: <https://doi.org/10.51583/IJLTEMAS.2025.141000016>

**Abstract:** Phytopharmaceuticals represent a promising fusion of contemporary scientific advancements and traditional plant-based knowledge. These products are rooted in the centuries-old herbal medicine systems of Ayurveda, Siddha, Unani, Sowa-Rigpa, and Naturopathy in India. The country's extensive ethnobotanical knowledge draws from the distinct therapeutic frameworks and bioactive insights provided by each of these traditions.

Despite this rich heritage, challenges remain in terms of clinical validation, standardization, quality control, and regulatory compliance. Unlike traditional AYUSH substances, India's regulatory framework for phytopharmaceuticals is evolving to ensure their efficacy, safety, and international recognition. As the global demand for plant-based medications continues to rise, phytopharmaceuticals are increasingly viewed as safer alternatives for existing and emerging medical conditions.

Advancements in AI-driven drug discovery, nanofabrication, and extraction technologies have accelerated the development of this field. Furthermore, regulatory reforms and mounting clinical evidence have established phytomedicine as a legitimate, evidence-based treatment option. Emerging trends highlight a shift toward ethical supply chains, sustainable sourcing, and personalized preventive healthcare.

With growing global markets and a critical role in addressing public health challenges, such as antimicrobial resistance (AMR), phytopharmaceuticals are poised for transformative growth. India, with its dual strengths in pharmaceutical innovation and traditional medicine, is uniquely positioned to spearhead this global movement.

**Keywords:** Phytopharmaceuticals, Ayurveda, Siddha medicine, Unani medicine, Regulatory framework, Indian pharmaceutical industry

## Overview of Phytopharmaceuticals and Their Significance

Medicinal products derived from plant materials that have undergone standardized processes to ensure quality, safety, and efficacy are referred to as phytopharmaceuticals, plant based pharmaceuticals, or botanical drugs. In contrast to traditional herbal remedies, which are often unrefined and lack accurate dosages, phytopharmaceuticals are standardized in composition, scientifically validated, and developed using modern extraction and analytical techniques.

There is a rising global interest in plant-derived medicines, fueled by changing health needs and market demand. This trend is driven by factors such as the growing demand for natural therapies, increasing incidence of chronic illnesses, antibiotic resistance, and heightened awareness of the adverse effects of synthetic drugs. Furthermore, the discovery of various bioactive plant compounds with strong therapeutic potential has accelerated due to advancements in photochemistry, biotechnology, and pharmacology. These developments have significantly influenced pharmaceutical approaches to drug discovery and development, positioning phytopharmaceuticals as promising alternatives or adjuncts to conventional medicines.

Phytopharmaceuticals must undergo rigorous pharmacological and clinical testing to be recognized by regulatory frameworks in many countries. For example, India's Drugs and Cosmetics Act classifies phytopharmaceuticals as a distinct category and mandates scientific validation, including toxicological and clinical data, prior to approval.

The significance of phytopharmaceuticals is rooted in the long history of their use in traditional medicine. Plant-based treatments have been used for centuries in systems such as Ayurveda, Traditional Chinese Medicine (TCM), and Unani. Many modern drugs trace their origins to botanical sources, with aspirin (from *Salix alba*), quinine (from *Cinchona officinalis*), and morphine (from *Papaver somniferum*) being notable examples. These cases highlight how the traditional use of medicinal plants, when validated by modern science, reveals the vast untapped potential of plant biodiversity as a resource for novel therapeutics.

The development of phytopharmaceuticals parallels that of synthetic drugs. It typically begins with the selection of medicinal plants, often guided by traditional use or ethnobotanical knowledge. Subsequently, bioactive compounds are extracted, isolated, and characterized using advanced techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy, Gas Chromatography–Mass Spectrometry (GC-MS), and High-Performance Liquid Chromatography (HPLC). Preclinical toxicology, pharmacokinetics, and clinical trials follow to ensure that safety, efficacy, and reproducibility are thoroughly established.

Phytopharmaceuticals are therapeutically used to treat various diseases, particularly chronic and lifestyle-related disorders. For instance, curcumin from *Curcuma longa* (turmeric) exhibits potent anti-inflammatory activity by modulating the NF- $\kappa$ B signaling pathway. Similarly, berberine from *Berberis aristata* has been shown to reduce blood glucose and cholesterol levels. Well-known

anticancer phytochemicals include taxol (from *Taxus brevifolia*) and vinca alkaloids (from *Catharanthus roseus*). These examples illustrate how the multitargeted mechanisms of phytopharmaceuticals can be harnessed to treat complex diseases.

Phytopharmaceuticals offer several advantages over conventional synthetic drugs. First, owing to their multi-component nature, they can act on multiple biological targets simultaneously, making them especially valuable for treating multifactorial conditions, such as cancer, diabetes, and neurodegenerative diseases. Second, their natural origin often leads to better patient tolerance and fewer side effects than synthetic drugs. Third, the synergistic interactions among plant compounds may reduce the likelihood of resistance, particularly in infectious diseases. Finally, when cultivated sustainably, phytopharmaceuticals are generally more environmentally friendly and resource-efficient.

### **An Overview of India's Diverse Knowledge Systems and Herbal Traditions**

India possesses one of the oldest and most comprehensive traditional medical systems in the world, grounded in deep observations of nature, plant properties, and their effects on human physiology.

#### **Ancient Roots and Fundamental Systems:**

India's herbal traditions trace back to the Vedic era (c. 1500–500 BCE), where references to medicinal plants and their uses are found in ancient texts such as the *Rig Veda* and the *Atharva Veda*. Over time, this foundational knowledge evolved into several distinctive and sophisticated medical systems, including:

#### **Ayurveda:**

"Ayurveda" translates to "Science of Life." It is the most prominent and widely practiced traditional medical system in India. Ayurveda views health as a balance among the three fundamental bodily humors or energies: Vata, Pitta, and Kapha. Disease is believed to result from an imbalance in these doshas, and treatment aims to restore equilibrium through individualized interventions. Ayurvedic medicine includes an extensive pharmacopoeia of herbs, minerals, and animal-derived substances, often combined into complex polyherbal formulations.

#### **Siddha Medicine:**

Siddha is one of the oldest traditional systems, primarily practiced in South India, particularly in Tamil Nadu. It emphasizes alchemy and uses a wide range of herbs, minerals, metals, and animal products. Siddhas, ancient spiritual healers, believed that spiritual and physical perfection could be achieved through internal medicine and purification processes. Siddha medicine follows a humoral theory similar to Ayurveda and incorporates nine forms of matter (*Panchabootham* and their derivatives). Its formulations are known for complex processes that purify metals and convert them into potent therapeutic agents (*chendoorams* and *bhasmas*).

#### **Unani Medicine:**

Introduced to India by Arab and Persian scholars, Unani medicine is rooted in the ancient Greek system and revolves around the theory of four humors —blood, phlegm, yellow bile, and black bile. Over the centuries, it has flourished in India under royal patronage and has integrated well with indigenous medical systems.

#### **Sowa-Rigpa:**

Also known as Tibetan Medicine, Sowa-Rigpa is practiced in the Himalayan regions of India. It is based on balancing five cosmic elements and three humors (*Nyepa*) and incorporates concepts from Ayurveda and Traditional Chinese Medicine. Its treatments include complex polyherbal preparations, dietary guidance and lifestyle modifications.

#### **Naturopathy and Yoga:**

Although not strictly herbal systems, Yoga and Naturopathy are integral to India's holistic health philosophy. Yoga, a spiritual and physical discipline, includes asanas (postures), pranayama (breathing techniques), and meditation, promoting overall wellness. Naturopathy emphasizes the body's self-healing capacity through natural therapies, such as hydrotherapy, fasting, mud therapy, dietary interventions, and minimal drug use. Both systems often support herbal therapies by promoting general detoxification and vitality.

#### **Challenges and Quality Standards:**

Despite its rapid growth, the phytopharmaceutical industry continues to face significant challenges. These include the sustainability of raw material supply, overharvesting of wild species, slow regeneration of medicinal plants, and regulatory standardization. To address these issues, adherence to pharmacopoeial standards is critical. These standards involve strict protocols for plant identification, sampling, and bioassays (such as thin-layer chromatography [TLC], High-Performance Liquid Chromatography [HPLC], and microbial and contaminant testing).

**Table 1:** Challenges and Quality Standards of Phytopharmaceuticals Agents

Phytopharmaceutical Drug	Botanical Source	Key Development Challenges	Quality Standards Required
Curcumin	<i>Curcuma longa</i>	Low bioavailability and rapid metabolism	HPLC content uniformity, particle size in nanoformulations, assay of curcuminoids.
Withanolides	<i>Withania somnifera</i>	Variability in withanolide content & poor formulation standardization	Marker-based quantification (Withaferin A), pesticide residue analysis, microbial load testing.
Gymnemic Acids	<i>Gymnema sylvestre</i>	Seasonal Fluctuation in active content, lack of clinical dosing standardization	Titration of gymnemic acid content, Testing of heavy metals and residual solvent
Guggulsterones	<i>Commiphora wightii</i>	Overharvesting, resin variability in composition, and poor water solubility	TLC/HPTLC standardization, analysis of gum-resin composition ratio
Boswellic Acids	<i>Boswellia serrata</i>	Instability of active acids and difficulty in isomer standardization	HPLC analysis of 11-keto- $\beta$ -boswellic acid, aflatoxin screening, and heavy metal analysis
Bacosides	<i>Bacopa monnieri</i>	Inconsistent extraction yield and Poor systemic availability	Quantification of Bacoside A and B , Stability testing under various storage conditions
Phyllanthin	<i>Phyllanthus niruri</i>	Confusion due to multiple species and standardised marker.	Standardized extract by HPLC (phyllanthin), Species verification by macroscopic/microscopic techniques
Picosides	<i>Picrorhiza kurroa</i>	Endangered plant status, poor cultivation, low yield	Identification via TLC, estimation of Picoside I & II
Tinosporaside	<i>Tinospora cordifolia</i>	Taxonomical confusion with related species, contamination issues	Tinosporaside estimation, Testing of mycotoxins and pesticide residues.
Berberine	<i>Berberis aristata</i>	Bitter taste, poor water solubility, and potential gastrointestinal irritation	HPLC assay of berberine , residual solvent analysis and stability testing.
Arjunolic Acid	<i>Terminalia arjuna</i>	Inconsistency in triterpenoids content and lack of standardized clinical dosage consistency	Triterpenoid fingerprinting via HPTLC, analysis of tannin content
Azadirachtin	<i>Azadirachta indica</i>	Degradation due to heat and light exposure; storage instability	HPLC quantification, testing for residual solvents and pesticide residue
Eugenol	<i>Ocimum sanctum</i>	Volatility, extraction challenges and formulation stability issue	GC-MS analysis, stability testing under temperature and humidity stress

**NDIA'S Phytopharmaceutical Regulation:**

India, with its rich legacy of traditional medical systems, has been working to bridge the gap between ancient wisdom and modern pharmaceutical sciences. This effort has led to the emergence of a distinct regulatory framework for phytopharmaceuticals, which are standardized plant-based drugs developed using scientific methods. Unlike Ayurvedic, Siddha, Unani, and Homoeopathic (AYUSH) medicines, which are governed by the Ministry of AYUSH, phytopharmaceuticals fall under a dual model that recognizes their plant-based origins but requires them to meet the same rigorous scientific standards as synthetic drugs.

Historically, herbal formulations in India were regulated under the Drugs and Cosmetics Act of 1940 and Rules of 1945, but the level of scrutiny was often less stringent than that applied to allopathic medicines. While the Ministry of AYUSH continues to regulate traditional systems such as Ayurveda, Siddha, and Unani, the global resurgence in interest in plant-based therapies and advancements in phytochemical research have created the need for a regulatory pathway tailored to scientifically validated herbal drugs. The lack of a clear legal and scientific structure to govern such products has long been a bottleneck for innovation and global competitiveness among Indian phytopharmaceutical companies.

In response, amendments were made to the Drugs and Cosmetics Rules, 1945, to formally introduce the term "Phytopharmaceutical". According to Rule 2(f) (as amended by G.S.R. 789(E), dated November 23, 2017), a phytopharmaceutical drug is defined as a plant-based drug that has been purified and standardized, containing at least four bioactive phytochemical compounds (biomarkers) with known or established therapeutic activity. These compounds may exist as individual components or as part of a fraction of the plant extract.

The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, is the designated regulatory body for phytopharmaceuticals, along with its responsibilities for allopathic drugs, vaccines, and medical devices. This distinction means that phytopharmaceuticals are subject to more stringent oversight than AYUSH medicines.

The regulatory pathway for phytopharmaceuticals closely resembles that of new chemical entities (NCEs) and involves rigorous data submission. Preclinical requirements include comprehensive pharmacology, toxicology, and pharmacokinetic studies. Pharmacological evaluation involves detailed *in vitro* and *in vivo* studies to substantiate the therapeutic efficacy and mechanisms of action. Toxicological studies assess safety through acute, subacute, and chronic toxicity trials, including genotoxicity, mutagenicity, and carcinogenicity tests. Pharmacokinetics assesses the absorption, distribution, metabolism, and excretion (ADME) profiles of active phytochemicals and their metabolites.

Standardization is critical because of the natural variability of plant-derived compounds. Raw materials must be controlled for their source, botanical identity, cultivation or collection methods, and preliminary processing. They are tested for contaminants such as pesticides, heavy metals, microbes and foreign matter. Extracts undergo phytochemical profiling using advanced analytical techniques (e.g., HPLC, GC-MS, LC-MS, NMR, HPTLC) to create chemical "fingerprints". Biomarker quantification ensures that at least four bioactive compounds are consistently present, guaranteeing batch-to-batch uniformity. Finished product quality control includes testing for identity, potency, dissolution, disintegration, and microbial contamination. Stability studies, in line with the International Council for Harmonisation (ICH) guidelines, determine the product shelf life under different environmental conditions.

Like synthetic drugs, phytopharmaceuticals must undergo phase clinical trials. In Phase I, safety and pharmacokinetics are assessed in healthy volunteers. Phase II evaluates efficacy and determines the optimal dosage in patients. Phase III involves large-scale, multi-center trials to confirm safety and efficacy and compare the results with those of conventional treatments. However, if a plant has a well-established record of traditional use and sufficient modern safety data, Phase I or II trials may be relaxed. However, Phase III trials are typically required for regulatory approval.

Manufacturers must comply with Good Manufacturing Practices (GMP), covering all aspects of production, from raw materials and facilities to staff training and hygiene. A detailed dossier in Common Technical Document (CTD) format must be submitted, containing clinical, non-clinical (toxicology and pharmacology), and Chemistry, Manufacturing, and Controls (CMC) data.

**Regulatory Distinction from Ayush Medicines:**

Understanding the regulatory differences between phytopharmaceuticals and AYUSH medicines is essential. Phytopharmaceuticals are regulated by the CDSCO under the Ministry of Health and Family Welfare, whereas AYUSH medicines fall under the Ministry of AYUSH. Phytopharmaceuticals require comprehensive preclinical studies, clinical trial data, and standardization (especially of biomarkers), aiming for reproducibility and scientific validation. In contrast, while quality control exists for AYUSH products, clinical trials and rigorous scientific validation are not always mandatory.

Claims made by phytopharmaceuticals must be supported by modern clinical evidence, while AYUSH claims are typically based on classical texts. Phytopharmaceutical product labels and indications are more aligned with modern drug standards. AYUSH formulations are categorized as "Classical Ayurvedic Medicine," "Proprietary Ayurvedic Medicine," and similar designations. This regulatory distinction allows India to preserve its traditional healthcare systems while encouraging innovation in scientifically validated, globally accepted plant-based medicines.

A notable regulatory advancement is the inclusion of a dedicated section on Phytopharmaceutical Ingredients (PPIs) in the Indian Pharmacopoeia (IP) 2022. These monographs offer standards for identifying, quantifying, and ensuring the purity of specific phytopharmaceutical compounds. Detailed analytical methods for biomarker evaluation are provided, promoting industry-wide quality control and smoother global acceptance. This move by the Indian Pharmacopoeia Commission (IPC) reinforces regulatory clarity and strengthens the credibility of Indian phytopharmaceutical products.

With a well-defined regulatory framework, increased R&D investment from both academia and the pharmaceutical industry is expected. Aligning with CDSCO and ICH guidelines enhances the global acceptability of Indian phytopharmaceuticals. The regulatory structure also supports bridging traditional knowledge and modern medicine, encouraging innovation in drug discovery by identifying novel bioactive leads from traditionally used plants. Furthermore, the emphasis on raw material quality promotes ethical and sustainable sourcing of medicinal plants.

**Current Status of The Phytopharmaceutical Industry in India:**

With increasing global demand for natural and plant-based medicines, rising awareness of the adverse effects of synthetic drugs, and a renewed focus on preventive and holistic healthcare, the phytopharmaceutical industry in India is experiencing a significant. This rapid expansion is driven by multiple interconnected factors.

One of the key drivers is the growing global preference for natural, organic, and plant-based products aimed at promoting health and wellness. This trend includes not only phytomedicines but also functional foods and herbal supplements. In parallel, rising concerns over the side effects, drug resistance, and high costs associated with conventional synthetic drugs are prompting consumers to seek safer, nature-derived Alternatives.

The Indian government has played a proactive role in supporting this growth through policy initiatives, financial incentives, and infrastructure development. Key efforts include promoting research and development, cultivation of medicinal plants, and product standardization. Agencies like the Ministry of AYUSH, the CSIR Phytopharmaceutical Mission, and the National Medicinal Plants Board (NMPB) are at the forefront of these initiatives. The inclusion of a dedicated section on Phytopharmaceutical Ingredients (PPI) in the Indian Pharmacopoeia 2022 marks an important milestone, signalling formal recognition and encouraging quality standardization.

India’s rich biodiversity and vast traditional knowledge base provide a unique competitive advantage. The country’s ecosystems support a wide array of medicinal plants, while its centuries-old herbal traditions offer a wealth of ethnomedicinal insights. Together, these elements facilitate the discovery of new botanical sources and the scientific validation of age-old remedies.

Further boosting the sector is the increased investment in research and development by Indian pharmaceutical companies and academic institutions. Advanced R&D is being used to isolate, characterize, and standardize bioactive plant compounds. Technologies such as novel drug delivery systems, modern extraction techniques, and sophisticated analytical tools are playing a pivotal role in elevating product quality and efficacy.

Phytopharmaceuticals also offer cost-effective therapeutic alternatives compared too many highly patented synthetic drugs. Their affordability enhances access for larger sections of the population, both in India and globally. At the same time, there is a growing global interest in integrative medicine, a healthcare approach that combines traditional and modern systems to provide holistic patient care. This has led to increased acceptance and demand for scientifically validated herbal products.

However, despite these promising developments, the Indian phytopharmaceutical sector still faces several challenges. Ensuring consistent quality, purity, and potency of plant-based raw materials and final products remains a key hurdle due to natural variability in plant species, geographic sources, cultivation methods, and post-harvest processing. Issues such as adulteration and contamination further complicate quality assurance.

Like synthetic drugs, modern phytopharmaceutical development requires comprehensive preclinical and clinical trials to establish safety, efficacy, and appropriate dosage. This process, although essential, can be both expensive and time-consuming, even when traditional use provides a historical basis for efficacy.

Additionally, protection of traditional knowledge and prevention of biopiracy remain pressing concerns, despite initiatives like the Traditional Knowledge Digital Library (TKDL) that aim to safeguard indigenous knowledge systems. There is also a pressing need to ensure ethical and sustainable sourcing of medicinal plants, especially those harvested from the wild. Overharvesting and habitat degradation pose significant threats to ecological balance and long-term supply.

While India has developed a structured regulatory framework for phytopharmaceuticals, differences in global regulatory standards continue to create challenges for international trade and export. To bridge the gap between traditional practices and modern drug development, strong interdisciplinary collaboration and robust scientific methodologies are essential.

**Table 2:** Current Phytopharmaceuticals Drugs and Formulations in India

Drug Name	Botanical Source	Formulation Type	Preparation Method	Therapeutic Use	Indian Manufacturer
-----------	------------------	------------------	--------------------	-----------------	---------------------

BGR-34	<i>Berberis aristata</i> , <i>Tinospora cordifolia</i>	Tablet	Hydro-alcoholic extraction, spray drying, blending, tablet compression	Type II diabetes management	Developed by CSIR, Marketed by AIMIL Pharmaceuticals
Ayush-64	<i>Alstonia scholaris</i> , <i>Picrorhiza kurroa</i>	Tablet	Decoction followed by drying of aqueous extract; compressed into tablets	Antimalarial; also used in COVID-19 management	Developed by CCRAS; part of AYUSH COVID-19 protocol
Liv.52	<i>Capparis spinosa</i> , <i>Cichorium intybus</i>	Syrup, Tablet	Maceration, percolation of aqueous and ethanol extracts, then formulation into syrup/tablets	Hepatoprotective, liver disorders	Himalaya Drug Company
Cystone	<i>Didymocarpus pedicellata</i> , <i>Saxifraga ligulata</i>	Tablet	Aqueous extraction, concentration, mixing with excipients, compression into tablets	Kidney stones, urinary tract disorders	Himalaya Drug Company
Diabecon	<i>Gymnema sylvestre</i> , <i>Pterocarpus marsupium</i>	Tablet	Solvent extraction, filtration, spray-drying, granulation, compression	Diabetes management	Himalaya Drug Company
Himcolin Gel	<i>Withania somnifera</i> , <i>Mucuna pruriens</i>	Topical Gel	Ethanol extraction of plant actives, mixing with gelling agents and excipients	Erectile dysfunction, sexual wellness	Himalaya Drug Company
Zandu Pancharishta	Multiple herbs ( <i>Dashamula</i> , <i>Triphala</i> )	Liquid tonic	Traditional fermentation, decoction, and aging in steel tanks	Digestive health, GI disorders	Zandu
REVERCIL	<i>Curcuma longa</i> (Curcumin)	Capsule	Supercritical CO <sub>2</sub> extraction, nano-encapsulation for bioavailability	Anti-inflammatory, liver fibrosis, cancer	Pharmanza Herbals

### Key Phytopharmaceuticals Items and Their Medical Uses:

India's rich legacy of traditional medical systems, such as Ayurveda, Siddha, and Unani, has contributed to an extensive repository of medicinal plants. With the establishment of a well defined regulatory framework for phytopharmaceuticals, there is now a concerted effort to scientifically validate these traditional remedies and integrate them into the modern pharmaceutical market.

While many herbal products remain classified under traditional or alternative medicine, several well researched plant-based compounds are gaining prominence within India's phytopharmaceuticals sector. These lead candidates are increasingly becoming the focus of rigorous research and development, with potential applications in evidence-based therapeutics.

It is important to note that a "phytopharmaceutical product," as defined by the CDSCO (Central Drugs Standard Control Organization) refers to a purified and

standardized extract or fraction derived from a medicinal plant, which must contain a minimum of four bioactive markers. Such a product is required to undergo extensive preclinical and clinical evaluation before being granted marketing approval, distinguishing it from traditional AYUSH formulations or general herbal supplements.

As regulatory standards become more stringent, the number of approved phytopharmaceutical drugs meeting the criteria for new drug approval, complete with validated clinical trial data, is steadily increasing in India. This growth reflects not only regulatory maturation but also an expansion of research activities centered on plant-derived compounds with proven pharmacological potential.

Below are some notable examples of medicinal plants and their active constituents that are at the forefront of current phytopharmaceuticals research and clinical application in India.

**Table 3:** Key Plant-Based Phytopharmaceuticals and Their Medical Applications

Plant	Biomarkers	Dosage Form	Therapeutic Indication
<i>Andrographis paniculata</i>	Andrographolide, andrograpanin, neo-andrographolide, 14-deoxy-11,12-didehydroandrographolide	Tablet / Capsule	Immune support, anti-inflammatory
<i>Cocculus hirsutus</i> (AQCH extract)	Multiple antiviral compounds (flavonoids, lignans); ongoing clinical trials	Oral extract (Phase 3)	Antiviral (COVID-19, dengue)
<i>Terminalia arjuna</i>	Arjunolic acid, arjunetin, arjunone, luteolin	Tablet /Capsule	Cardioprotective, antihypertensive
<i>Curcuma longa</i> (Turmeric)	Curcumin, demethoxycurcumin, bisdemethoxycurcumin, turmerone	Tablet / Phytosome / Topical	Anti-inflammatory, anticancer
<i>Bacopa monnieri</i>	Bacoside A, bacopaside II, bacopasaponin C, bacopaside X	Capsule / Syrup	Cognitive enhancement, neuroprotective
<i>Withania somnifera</i> (Ashwagandha)	Withaferin A, withanolide A, withanoside IV, withanolide D	Capsule / Granules	Adaptogen, anti-stress, anxiolytic
<i>Boswellia serrata</i>	11-keto- $\beta$ -boswellic acid, acetyl-11-keto- $\beta$ -boswellic acid, $\beta$ -boswellic acid, $\alpha$ -boswellic acid	Sustained-release tablet	Osteoarthritis, anti-inflammatory
<i>Ocimum sanctum</i> (Tulsi)	Eugenol, ursolic acid, rosmarinic acid, apigenin	Oral strips / Capsule	Respiratory health, anti-allergy
<i>Gymnema sylvestre</i>	Gymnemic acid I–IV, gymnemoside A, gymnemasaponins	Capsule / Extract	Anti-diabetic, sugar metabolism
<i>Emblica officinalis</i> (Amla)	Ascorbic acid, ellagic acid, gallic acid, emblicanin A & B	Juice / Effervescent tablet	Antioxidant, immune support

**Future Prospects of Phytopharmaceuticals:**

Phytopharmaceuticals are rapidly emerging as a significant segment within the global healthcare industry, particularly as a complementary and alternative therapy. Rooted in ancient traditional systems like Ayurveda, Traditional Chinese Medicine (TCM), and Kampo, these plant-based drugs are gaining recognition through advancements in biotechnology, modern research, and evolving regulatory frameworks. As the global demand grows for safer, sustainable, and natural treatment options, the future of phytopharmaceuticals appears both promising and strategically valuable—for public health and economic development alike.

**Growing Interest in Safer, Natural Therapies:**

One of the primary drivers of phytopharmaceutical growth is the increasing global shift toward natural, plant-based healthcare solutions. Rising concerns over the long-term side effects of synthetic drugs have led both patients and healthcare providers to seek safer and more holistic alternative. Phytopharmaceuticals, known for their multi-target therapeutic effects and relatively low risk of adverse reactions, are especially favoured in the long-term treatment of chronic conditions such as diabetes, arthritis, cardiovascular diseases, and neurological disorders.

Simultaneously, the global focus on preventive healthcare and wellness is growing. The anti-inflammatory, antioxidant, and immunomodulatory properties of phytopharmaceuticals align well with these trends, expanding their use across both therapeutic and wellness markets.

**Clinical Validation and Scientific Evidence:**

Historically, plant-based medicines struggled with mainstream acceptance due to a lack of scientific evidence. However, recent years have seen a surge in robust preclinical and clinical studies aimed at building credible evidence bases. Botanical compounds are now being investigated through advanced pharmacological testing, toxicological evaluations, and randomized controlled trials (RCTs)

In India, the Central Drugs Standard Control Organization (CDSCO) has made it possible to approve phytopharmaceuticals based on scientific validation through amendments such as Rule 170 (Schedule Y, 2015). Globally, agencies like the USFDA and EMA are also recognizing botanical drug applications, which is further enhancing credibility and facilitating broader acceptance.

**Advances in Extraction and Formulation Technologies:**

Modern technology is playing a transformative role in the development of phytopharmaceuticals. Advanced extraction methods such as microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), and supercritical fluid extraction (SFE) have improved the yield, purity, and consistency of bioactive compounds, all essential for therapeutic efficacy and regulatory compliance.

Additionally, nanotechnology is revolutionizing formulation techniques. Drug delivery systems using nanoparticles, liposomes, and nanoemulsions enhance the bioavailability, stability, and targeted delivery of plant-derived compounds, making phytopharmaceuticals more competitive with synthetic drugs.

#### **Integration into Modern Drug Discovery Platforms:**

An emerging trend is the integration of phytopharmaceutical research into modern drug discovery systems. Tools like cheminformatics, bioinformatics, high-throughput screening, and artificial intelligence (AI) are being used to analyze large databases of medicinal plants. These technologies help identify potential lead compounds and predict interactions with biological targets, significantly reducing development time and costs.

AI modeling also allows researchers to simulate toxicity profiles and pharmacokinetics, accelerating the journey from traditional knowledge to market-ready drugs. As a result, pharmaceutical companies are increasingly investing in phytopharmaceutical pipelines, supported by multidisciplinary collaborations between pharmacologists, ethnobotanists, and data scientists.

#### **International Market Potential and Export Opportunities:**

The global phytopharmaceutical market is projected to grow at a compound annual growth rate (CAGR) exceeding 10% through 2030. Countries like India, endowed with rich biodiversity and a legacy of traditional medicine, are well-positioned to capitalize on this expansion.

Initiatives such as Ayushman Bharat and the National AYUSH Mission are promoting the development, production, and export of AYUSH and phytopharmaceutical products. Demand is particularly high in regions like Europe, North America, and Southeast Asia, where natural therapies are increasingly being integrated into formal healthcare systems. Companies are now registering botanical drugs under pathways like the USFDA and filing for international patents to enhance export potential.

#### **Ethical Sourcing and Sustainability:**

As the industry grows, sustainability and ethical sourcing are becoming vital. Challenges such as habitat destruction, overharvesting, and poor traceability of raw materials threaten long-term viability. Solutions include the adoption of Good Agricultural and Collection Practices (GACP), cultivation-based supply chains, and biotechnological tools like tissue culture and genetic fingerprinting to ensure consistency and sustainability.

Equally important is benefit-sharing with indigenous communities who have preserved traditional knowledge. Global frameworks like the Nagoya Protocol promote fair collaboration among knowledge holders, researchers, and industry stakeholders.

#### **Addressing Emerging Health Challenges:**

Phytopharmaceuticals also offer promising solutions to contemporary health threats, including viral infections, lifestyle diseases, and antimicrobial resistance (AMR). Many plant-derived compounds have shown potential in targeting drug-resistant bacteria and viruses, including those associated with COVID-19. Research continues into phytopharmaceutical adjuvants that may enhance the effectiveness of conventional therapies.

#### **Emerging Trends in Phytopharmaceuticals:**

Phytopharmaceuticals, scientifically validated, regulator-approved drugs derived from plants, are reshaping the global healthcare landscape. Unlike traditional herbal remedies, which rely on empirical knowledge and crude extracts, phytopharmaceuticals are standardized, clinically tested, and manufactured under strict quality controls.

The following trends are driving their future:

#### **Innovations in Extraction and Formulation:**

Advanced technologies are replacing conventional extraction methods, which often yielded inconsistent results. Techniques such as Supercritical Fluid Extraction (SFE), Ultrasound-Assisted Extraction (UAE), and Microwave-Assisted Extraction (MAE) offer higher precision, efficiency, and environmental sustainability.

In formulation, nanotechnology is enabling new delivery systems such as polymeric nanoparticles, nanoencapsulation, and liposomal carriers. These innovations enhance the stability and bioavailability of compounds. For example, curcumin—known for low bioavailability—is now formulated with nanocarriers to improve its therapeutic potential.

#### **Use of Computational Tools and AI in Drug Discovery:**

AI, machine learning, and bioinformatics are becoming integral in phytopharmaceutical research. By analyzing vast datasets of phytochemicals and their properties, these tools can accurately predict pharmacological effects, toxicity, and target interactions.

Techniques like molecular docking and in silico simulations allow researchers to rapidly screen thousands of compounds, reducing dependency on time-consuming wet-lab procedures. This accelerates drug development, particularly for diseases like cancer, infections, and neurodegeneration.

**Rise of Evidence-Based Phytomedicine:**

Regulatory bodies and clinicians increasingly demand rigorous evidence for plant-based drugs. This has led to a surge in randomized controlled trials (RCTs), pharmacokinetic studies, toxicity assessments, and interaction analyses.

Such research is changing perceptions, elevating phytopharmaceuticals from traditional remedies to accepted therapies. For example, standardized extracts of *Boswellia serrata* and *Andrographis paniculata* are now clinically validated for treating joint inflammation and respiratory conditions.

**Regulatory Reforms and Global Harmonization:**

The legal landscape is evolving to accommodate phytopharmaceuticals. India’s inclusion of phytopharmaceuticals under Rule 170 (Drugs and Cosmetics Act, 2015), requiring scientific evidence for approval, has set a benchmark.

Internationally, regulatory harmonization is being encouraged by agencies such as the USFDA, EMA, and WHO. This facilitates global trade and compliance, creating opportunities for phytopharmaceutical producers in developing nations.

**Personalized and Preventive Phytomedicine:**

With the rise of precision medicine, phytopharmaceuticals are being tailored based on genetic, metabolic, and microbiome profiles. Tools such as pharmacogenomics and metabolomics are enabling the customization of plant-based therapies.

Moreover, the preventive focus of traditional medicine aligns well with current healthcare priorities. Phytopharmaceuticals are now being used to prevent or manage early-stage chronic conditions, immune dysfunctions, and metabolic disorders.

**Global Market Expansion:**

Countries with rich biodiversity and traditional medical systems such as India, Brazil, and China, are becoming key players in the phytopharmaceuticals industry. Exports are growing, particularly to Europe (due to high demand for natural products), North America (as the FDA begins recognizing botanical drugs), and resource-constrained regions in Africa and Latin America.

Indian firms are increasingly collaborating with multinational companies and registering phytopharmaceuticals with international regulatory bodies.

**Addressing Antimicrobial Resistance (AMR):**

Phytopharmaceuticals are being explored as alternatives to conventional antibiotics. Compounds like berberine, thymol, and allicin have demonstrated efficacy against resistant strains. Some are being developed as adjuvants to existing antibiotics, helping overcome resistance mechanisms, making this an urgent priority in the post-pandemic era.

**Sustainability And Ethical Access:**

Sustainability is central to the future of phytopharmaceuticals. Governments and industries are adopting GACP to ensure traceability, conservation, and quality of medicinal plants. Techniques like tissue culture, micropropagation, and metabolic engineering are reducing pressure on wild populations.

**Table 4:** Emerging Trends in Phytopharmaceuticals

Sr. No.	Emerging Trend	Technique	Herbal Drug
1	AI and Machine Learning in Drug Discovery	Application of deep learning models for phytochemical screening	<i>Withania somnifera</i>
2	Sustainable Extraction Technologies	Use of supercritical CO <sub>2</sub> extraction for efficient and eco-friendly processing	<i>Curcuma longa</i>
3	Nanotechnology-Based Drug Delivery	Nano-encapsulation and liposomal delivery systems to enhance bioavailability	Quercetin , Curcumin
4	Genomic and Metabolomic Integration	Utilization of transcriptomics and metabolomics for understanding plant biosynthetic pathways	<i>Panax ginseng</i>
5	Regulatory Harmonization	Alignment of regulatory guidelines across CDSCO, USFDA, and EMA	Standardized polyherbal formulations

<b>6</b>	Blockchain in Herbal Supply Chain	Implementation of QR code-based tracking and blockchain-enabled traceability	<i>Tinospora cordifolia</i>
<b>7</b>	CRISPR and Synthetic Biology	Use of CRISPR-Cas9 for genome editing in medicinal plants	<i>Artemisia annua</i>
<b>8</b>	Evidence-Based Clinical Validation	Conducting rigorous Phase I–III clinical trials to establish safety and efficacy	<i>Boswellia serrate</i>

### Conclusion:

Phytopharmaceuticals offer a scientific pathway to harness India’s vast heritage of medicinal plants for modern therapeutic use. As concerns over the side effects of synthetic drugs grow, there is increasing interest in safer, plant-based alternatives. Phytopharmaceuticals, grounded in centuries of traditional knowledge and supported by emerging research, provide a compelling solution.

India’s rich healing traditions, Ayurveda, Siddha, Unani, Sowa-Rigpa, and Naturopathy have long used botanicals for treating various ailments. These culturally rooted systems offer a strong foundation for developing standardized, clinically validated plant-based medicines. The shift from traditional herbal use to scientifically supported phytomedicine is gaining momentum, but challenges remain. Ensuring quality control, standardizing active ingredients, authenticating raw materials, and maintaining consistency in outcomes are critical.

To address this, the Central Drugs Standard Control Organization (CDSCO) has established modern regulatory frameworks requiring clinical trials, toxicity testing, and pharmacological validation to distinguish phytopharmaceuticals from conventional AYUSH products. These regulations aim to boost consumer trust and global competitiveness.

India’s phytopharmaceutical sector is evolving rapidly, with growing investments in advanced extraction techniques, nano-formulations, and quality assurance. Popular herbs like *Boswellia serrata*, *Withania somnifera*, and *Curcuma longa* are gaining international recognition.

Future prospects include AI-assisted drug discovery, CRISPR-based plant enhancement, blockchain-based traceability, and strategies to combat antimicrobial resistance (AMR). Ethical sourcing, biodiversity conservation, and fair trade are also becoming central to sustainable growth.

In summary, phytopharmaceuticals blend traditional wisdom with modern science. India is uniquely positioned to lead this global movement toward safe, effective, and sustainable plant-based medicine.

### Acknowledgement:

The authors would like to express their gratitude to our institution's administration and faculty for their encouragement and support throughout the writing of this review. We would like to express our gratitude to all of the researchers whose work has advanced our knowledge of phytopharmaceuticals. We especially appreciate those who maintain and promote India's rich herbal traditions.

### References:

1. Abbas MKG, Rassam A, Karamshahi F, et al. The role of AI in drug discovery. *Chembiochem*. 2024;25(14):e202300816. doi:10.1002/cbic.202300816
2. Abhilash MB, Kumar D, Deepti A, et al. Enhanced absorption of curcuminoids and 3-Acetyl-11-keto-β-boswellic acid from fenugreek galactomannan hydrogel beadlets: A natural approach to the co-delivery of lipophilic phytonutrients. *J Funct Foods*. 2021;79:104405. doi:10.1016/j.jff.2021.104405
3. Adepoju FO, Duru KC, Li E, Kovaleva EG, Tsurkan MV. Pharmacological potential of betulin as a multitarget compound. *Biomolecules*. 2023 Jul 12;13(7):1105. doi:10.3390/biom13071105.
4. Adhikari A, Dey A, Kanjilal S, et al. Gastroprotective and digestive potential of an Ayurvedic asava–arishta preparation. *Orient Pharm Exp Med*. 2018;18:391–401. <https://doi.org/10.1007/s13596-018-0325-y>
5. Adhikari S, Nath P, Deb VK, et al. Pharmacological potential of natural chalcones: a recent studies and future perspective. *Front Pharmacol*. 2025;16:1570385. doi:10.3389/fphar.2025.1570385
6. Afyouni I, Ghanbarikondori P, Pour NS, et al. Studying the Characteristics of Curcumin-Loaded Liposomal Nanoparticles. *Asian Pac J Cancer Biol*. 2024;9(2):183–189. doi:10.31557/APJCB.2024.9.2.183-189
7. Ahmad M, Tahir M, Hong Z, Zia MA, Rafeeq H, Ahmad MS, Rehman SU, Sun J. Plant and marine-derived natural products: sustainable pathways for future drug discovery and therapeutic development. *Frontiers in Pharmacology*. 2025 Jan 6;15:1497668. doi:10.3389/fphar.2024.1497668
8. Alghamdi MA, Fallica AN, Virzi N, et al. The Promise of Nanotechnology in Personalized Medicine. *J Pers Med*. 2022;12(5):673. doi:10.3390/jpm12050673
9. Al-Hasawi NA, Al-Tannak NF, Joy J, Orabi KY. Bioactivity-guided fractionation of *Withania somnifera* (L.) Dunal roots extract: evaluation of the anti-progressive potential on human Kelly neuroblastoma cell line. *BMC Complementary Medicine and Therapies*. 2025 Jul 16;25:267. doi:10.1186/s12906-025-05018-2.

10. Ansari SH, Islam F, Sameem M. Influence of nanotechnology on herbal drugs: A Review. *Journal of advanced pharmaceutical technology & research*. 2012 Jul 1;3(3):142-6.doi:10.4103/2231-4040.101006
11. Ashraf MV, Pant S, Khan MAH, et al. Phytochemicals as Antimicrobials: Prospecting Himalayan Medicinal Plants as Source of Alternate Medicine to Combat Antimicrobial Resistance. *Pharmaceuticals*. 2023;16(6):881. doi:10.3390/ph16060881
12. Assouguem A, Annemer S, Mohammed K, Lazraq A. Innovative Approaches in the Extraction, Identification, and Application of Secondary Metabolites from Plants. *Phyton*. 2025;94(6):1631. DOI:10.32604/phyton.2025.065750
13. Balkrishna A, Sharma N, Srivastava D, Kukreti A, Srivastava S, Arya V. Exploring the safety, efficacy, and bioactivity of herbal medicines: bridging traditional wisdom and modern science in healthcare. *Future Integrative Medicine*. 2024 Mar 28;3(1):35-49.doi:10.14218/FIM.2023.00086
14. Ball BJ, Xiao W, Borthakur G, Nguyen LX, Valerio M, Venkatachalam A, Marcucci G, Stein AS, Thai DL, Cook DN, Chan K. Phase I first-in-human dose escalation study of the oral casein kinase 1 $\alpha$  and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML. *Journal of Hematology & Oncology*. 2025 Jul 15;18(1):73. doi:10.1186/s13045-025-01724-z.
15. Basch E, Boon H, Heerema TD, et al. *Boswellia*: An Evidence-Based Systematic Review by the Natural Standard Research Collaboration. *J Herb Pharmacother*. 2004;4(3):63–83. doi:10.1080/J157v04n03\_06
16. Basso J, Chen KJ, Zhou Y, Mark L, LaSala D, Dorfman A, Atalla M, Chun D, Viramontes V, Chang C, Leifer F. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species. *Frontiers in Pharmacology*. 2023 Jul 19;14:1208780.doi:10.3389/fphar.2023.1208780.
17. Baveja M. *Phytopharmaceuticals for Management of Disorders*. In: Khoobchandani M, Ghosh S, editors. *Medicinal Applications of Phytopharmaceuticals*. Cham: Springer; 2024. doi:10.1007/978-3-031-63677-6\_2
18. Beladiya JV, Mehta AA. Acute and 28-days subacute toxicity studies of Gaq-RGS2 signaling inhibitor. *Laboratory Animal Research*. 2021 Jul 26;37(1):17. doi:10.1186/s42826-021-00093-1.
19. Beressa TB, Gadisa DA, Mammo S, et al. Ethnobotanical study of traditional medicinal plants used to treat human ailments in West Shewa community, Oromia, Ethiopia. *Front Pharmacol*. 2024;15:1369480. doi:10.3389/fphar.2024.1369480
20. Bhadange YA, Carpenter J, Saharan VK. A comprehensive review on advanced extraction techniques for retrieving bioactive components from natural sources. *ACS omega*. 2024 Jul 8;9(29):31274-97.https://doi.org/10.1021/acsomega.Ac02718
21. Bhatt A. *Phytopharmaceuticals: A new drug class regulated in India. Perspectives in clinical research*. 2016 Apr 1;7(2):59-61.doi:10.4103/2229-3485.179435.
22. Bhattacharya NS. Recent developments in herbal drug standard in India. *International Journal of Complementary and Alternative Medicine*. 2019;12(5):186-8. doi:10.15406/ijcam.2019.12.00471.
23. Bhosale VV, Banerjee D. Scientific validation of herbal medicine. In: Banerjee D, editor. *Herbal Medicine in India: Indigenous Knowledge, Practice, Innovation and its Value*. Singapore: Springer Singapore; 2019. p. 573–9. https://doi.org/10.1007/978-981-13-7248-3\_34
24. Bhowmik D, Kumar KS, Tripathi P, Chiranjib B. Traditional herbal medicines: An overview. *Arch Appl Sci Res*. 2009;1(2):165–77.
25. Blaikie C. Currents of tradition in Sowa Rigpa pharmacy. *East Asian Science, Technology and Society: An International Journal*. 2013 Sep 1;7(3):425-51.https://doi.org/10.1215/18752160-2332223
26. Busia K. Herbal medicine dosage standardisation. *Journal of Herbal Medicine*. 2024 Aug 1;46:100889.doi:10.1016/j.hermed.2024.100889.
27. Cao S, Liang J, Chen M, et al. Comparative analysis of extraction technologies for plant extracts and absolutes. *Front Chem*. 2025;13:1536590. doi:10.3389/fchem.2025.1536590
28. Chakraborty P. An Investigational Study on Factors of Quality Culture in Pharmaceutical Manufacturing Sectors. *Shanlax Int. J. Manag*. 2022;9:146-54.doi:10.34293/management.v9iS1.4855.
29. Chanchal DK, Porwal P, Singh G. The development of Ayurveda: From ancient practice to modern fad. *Int J Pharm Sci Med*. 2023;1(1):23–31. doi:10.70199/IJPSM.1.1.23-31
30. Chandra S, Narayana DBA. Evaluation of drug standards, quality control, and trade in medicinal plants. *J Res Ayurvedic Sci*. 2023;7(1):13-20doi:10.4103/jras.jras\_151\_22.
31. Chebabe M, Elkhoudri N, Chahboune M, Laamiri FZ, Marc I, Mochhoury L. Study of chemical characterization of medicinal plants used for traditional medicine: A review. *Biomed Pharmacol J*. 2025;18(1). doi:10.13005/bpj/3106
32. Cheng JT, Liu IM, Shen SC. *Plant Therapeutics*. *Plants*. 2022;11(20):2720. doi:10.3390/plants11202720
33. Chihomvu P, Ganesan A, Gibbons S, Woollard K, Hayes MA. Phytochemicals in drug discovery—A confluence of tradition and innovation. *International journal of molecular sciences*. 2024 Aug 13;25(16):8792.doi:10.3390/ijms25168792
34. Dadhich MK, Sanwal CS, Mahajon B, Vaishya JK, Dutt S, Rath C, Sharma S, Tyagi K, Dwivedi H, Shukla CP, Murugeswaran R. Contributions of the National Medicinal Plants Board (NMPB), Ministry of Ayush in the medicinal plants sector-An appraisal. *International Journal of Ayurveda Research*. 2024 Apr 1;5(2):62-75.doi:10.4103/ijar.ijar\_59\_24.

34. de Paula JA, Brito LF, Caetano KL, de Moraes Rodrigues MC, Borges LL, da Conceição EC. Ultrasound-assisted extraction of azadirachtin from dried entire fruits of *Azadirachta indica* A. Juss.(Meliaceae) and its determination by a validated HPLC-PDA method. *Talanta*. 2016 Mar 1;149:77-84.doi:10.1016/j.talanta.2015.11.005.
35. De Silva HA, Saparamadu PAM, Thabrew MI, Pathmeswaran A, Fonseka MMD, De Silva HJ. Liv.52 in alcoholic liver disease: a prospective, controlled trial. *J Ethnopharmacol*. 2003;84(1):47-50. [https://doi.org/10.1016/S0378-8741\(02\)00263-5](https://doi.org/10.1016/S0378-8741(02)00263-5)
36. Degot P, Huber V, Hofmann E, et al. Solubilization and extraction of curcumin from *Curcuma Longa* using green, sustainable, and food-approved surfactant-free microemulsions. *Food Chem*. 2021;336:127660. doi:10.1016/j.foodchem.2020.127660
37. Dharshini MD, Sreelakshmi MS, Adithya J, Lakshmi PK, Nath LR. A systematic analysis of the ethnopharmacological relevance of an Indian traditional plant, *Hemidesmus indicus* (L.) R.Br. for the past 10 years. *J Appl Pharm Sci*. 2024;14(1):37-44. <http://doi.org/10.7324/JAPS.2024.159652>
38. Dou J, Weathers P. Specialty molecules from plants and in vitro cultures as new drugs: regulatory considerations from flask to patient. *Plant Cell, Tissue and Organ Culture (PCTOC)*. 2022 May;149(1):105-11.doi:10.1007/s11240-022-02287-4.
39. Dubale S, Usure RE, Mekasha YT, Hasen G, Hafiz F, Kebebe D, Suleman S. Traditional herbal medicine legislative and regulatory framework: a cross-sectional quantitative study and archival review perspectives. *Frontiers in Pharmacology*. 2025 Jan 30;16:1475297. doi:10.3389/fphar.2025.1475297.
40. Dutta RDG, Kar G, Rao S. Symposium of Herbs and their Therapeutic Implementations Present in Kadhaayu: A Novel Kadhaayu by Renuka. *Int J Pharm Sci Rev Res*. 2023;79(2):259-276. doi:10.47583/ijpsr.2023.v79i02.040
41. Dwivedi S. *Terminalia arjuna* Wight & Arn.—a useful drug for cardiovascular disorders. *J Ethnopharmacol*. 2007;114(2):114-129. doi:10.1016/j.jep.2007.08.003
42. Eddouks M, Chattopadhyay D, De Feo V, Cho WC. Medicinal plants in the prevention and treatment of chronic diseases 2013. Evidence-based Complementary and Alternative Medicine: eCAM. 2014 Mar 26;2014:180981.doi:10.1155/2014/180981
43. Edo GI, Obasohan P, Makia RS, et al. The use of quality control parameters in the evaluation of herbal drugs: A review. *Discov Med*. 2024;1:168. <https://doi.org/10.1007/s44337-024-00177-6>
44. El-Fitany RA, Khasawneh MA. *Leptadenia Pyrotechnica* (Forsk.) Decne: from edibility to drug discovery (a comprehensive review). *Food Reviews International*. 2023 Oct 3;39(9):6834-86.doi:10.1080/87559129.2022.2126853.
45. El-Saadony MT, Saad AM, Mohammed DM, Korma SA, Alshahrani MY, Ahmed AE, Ibrahim EH, Salem HM, Alkafaas SS, Saif AM, Elkafas SS. Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits—a comprehensive review. *Frontiers in immunology*. 2025 Apr 28;16:1491777. doi:10.3389/fimmu.2025.1491777
46. Erickson SB, Vrtiska TJ, Canzanello VJ, et al. Cystone® for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. *Urol Res*. 2011;39:197-203. <https://doi.org/10.1007/s00240-010-0334-x>
47. Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. *Evid Based Complement Alternat Med*. 2007;4(Suppl 1):37-40. <https://doi.org/10.1093/ecam/nem096>
48. Foudah AI, Alam A, Salkini MA, Ross SA, Kumar P, Aldawsari MF, Alqarni MH, Sweilam SH. Synergistic combination of letrozole and berberine in ascorbic acid-stabilized AuNPs: a promising solution for breast cancer. *Pharmaceuticals*. 2023 Aug 3;16(8):1099. doi:10.3390/ph16081099
49. Ghimire P, Shrestha AC, Pandey S. Guidelines on stability studies of pharmaceutical products and shelf life estimation. *Int J Adv Pharm Biotechnol*. 2020 Mar;6(1):15-23.doi.org/ 10.38111/ijapb.20200601004
50. Girme A, Saste G, Singh R, Mirgal A, Ingavale R, Balasubramaniam AK, Ghoshal S, Ghule C, Patel S, Verma MK, Maurya R. Quantitative and rapid quality assessment methods for the multi-class bioactive constituents of *Tinospora cordifolia* using high-performance liquid and thin layer chromatography analysis with tandem mass spectrometry characterization. *Separation Science Plus*. 2022 Aug;5(8):378-92.doi:10.1002/sscp.202200048.
51. Gopalaiah SB, Jayaseelan K. Analytical strategies to investigate molecular signaling, proteomics, extraction and quantification of withanolides—A comprehensive review. *Critical Reviews in Analytical Chemistry*. 2025 May 19;55(4):723-47.. doi:10.1080/10408347.2024.2307887
52. Goyal MR, Chauhan A. Holistic Approach of Nutrients and Traditional Natural Medicines for Human Health: A Review. *Future Integr Med*. 2024;3(3):197-208. doi: 10.14218/FIM.2023.00089.
53. Gupta R. Integrating ayurveda with modern medicine for enhanced patient care: Analysis of realities. *The Physician*. 2024 Apr 20;9(1):1-6.doi:10.38192/1.9.1.3.
54. Hossain MS, Wazed MA, Asha S, Amin MR, Shimul IM. Dietary phytochemicals in health and disease: Mechanisms, clinical evidence, and applications—a comprehensive review. *Food Science & Nutrition*. 2025 Mar;13(3):e70101. <https://doi.org/10.1002/fsn3.70101>
55. Huang L, Huang XH, Yang X, et al. Novel nano-drug delivery system for natural products and their application. *Pharmacol Res*. 2024;201:107100. doi:10.1016/j.phrs.2024.107100

56. Imran M, Najmi AK, Rashid MF, Tabrez S, Shah MA. Clinical research regulation in India—history, development, initiatives, challenges and controversies: Still long way to go. *J Pharm Bioall Sci*. 2013;5(1):2–9. doi:10.4103/0975-7406.106553
57. Inada I, Kiuchi F, Urushihara H. Comparison of regulations for arsenic and heavy metals in herbal medicines using pharmacopoeias of nine counties/regions. *Therapeutic Innovation & Regulatory Science*. 2023 Sep;57(5):963-74. doi:10.1007/s43441-023-00532-2.
58. International Journal of Science, Architecture, Technology, and Environment Volume 02, Issue 07, July 2025 DOI: <https://doi.org/10.63680/ijstate0625051.27>
59. Jadaun GP, Rastogi S, Kumar A, Chauhan J, Sharma SK, Kumar M, Saini PK, Tiwari R, Raghuvanshi RS. Ensuring the quality of medicines in India: An update on the development, modernization, and harmonization of drug standards in the Indian Pharmacopoeia. *Saudi Pharmaceutical Journal*. 2023 Dec 1;31(12):101825. doi:10.1016/j.jsps.2023.101825
60. Jain SD, Shrivastava SK, Agrawal A, Gupta AK. WHO guidelines for quality control of herbal medicines: From cultivation to consumption. *Internafional Journal of Pharmaceufical and Chemical Analysis*. 2024;11(3):212-25. doi:10.18231/j.ijpca.2024.031.
61. Joglekar S, Iyer SS, Parate R, et al. Efficacy and Safety of a Phytopharmaceutical Drug Derived from *Cocculus hirsutus* in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial. *Infect Dis Ther*. 2022;11:807–826. doi:10.1007/s40121-022-00604-0
62. Kanagarathinam DV, Lourdusamy JB. Rise of Siddha medicine: causes and constructions in the Madras Presidency (1920–1930s). *Medical History*. 2023 Jan;67(1):42–56. doi:10.1017/mdh.2023.10
63. Kandhare AD, Ghosh P, Ghule AE, Zambare GN, Bodhankar SL. Protective effect of *Phyllanthus amarus* by modulation of endogenous biomarkers and DNA damage in acetic acid induced ulcerative colitis: Role of phyllanthin and hypophyllanthin. *Apollo Medicine*. 2013 Mar;10(1):87–97. doi:10.1016/j.apme.2013.01.006
64. Kannaiyan S. Biological diversity and traditional knowledge. In Paper circulated for discussion at the National Consultation Workshop on Agro biodiversity Hotspots and Access and Benefit Sharing 2007 Jul (pp. 19–20).
65. Karunamoorthi K, Jegajeevanram K, Xavier J, Vijayalakshmi J, Melita L. Tamil traditional medicinal system-siddha: an indigenous health practice in the international perspectives. 2012 May;2(2):25–35. <https://doi.org/10.5667/TANG.2012.0006>
66. Kaur S, Goyal A, Rai A, Sharma A, Ugoeze KC, Singh I. Quercetin nanoformulations: recent advancements and therapeutic applications. *Advances in Natural Sciences: Nanoscience and Nanotechnology*. 2023 Sep 7;14(3):033002. doi:10.1088/2043-6262/acadaa
67. Khan F, Sarker MMR, Ming LC, et al. Comprehensive Review on Phytochemicals, Pharmacological and Clinical Potentials of *Gymnema sylvestre*. *Front Pharmacol*. 2019;10:1223. doi:10.3389/fphar.2019.01223
68. Khan MSA, Ahmad I. Herbal medicine: current trends and future prospects. In: Ahmad I, editor. *New Look to Phytomedicine*. Cambridge: Academic Press; 2019. p. 3–13. <https://doi.org/10.1016/B978-0-12-814619-4.00001-X>
69. Khare N, Khare P. The Future of Herbal Medicine: Research and Innovation. In: *Therapeutic Plants: Recent Advances in the Use of Herbs as Alternative Medications*. Bentham Science Publishers; 2025. p.1–23. doi:10.2174/9789815322910120101
70. Kilic M. The Healing Power of Plants for Health. In *Medicinal Plants-Harnessing the Healing Power of Plants* 2024 Aug 22. IntechOpen. doi:10.5772/intechopen.1005757
71. Kim SW, Gupta R, Lee SH, et al. An Integrated Biochemical, Proteomics, and Metabolomics Approach for Supporting Medicinal Value of *Panax ginseng* Fruits. *Front Plant Sci*. 2016;7:994. doi:10.3389/fpls.2016.00994
72. Koerniati S, Simanjuntak G. CRISPR/Cas9 system for disruption of biochemical pathway for sterol synthesis in *Artemisia annua* L. *IOP Conf Ser Earth Environ Sci*. 2020;482(1):012028. doi:10.1088/1755-1315/482/1/012028
73. Kulkarni H, Ghate U. Ayurveda and Herbs as “Fusion Medicines”: Alternatives or Adjuvants to Address Antimicrobial Resistance (AMR)- A Review. *Int J Biomed Clin Res*. 2025;3(3):1–7. doi:10.59657/2997-6103.brs.25.056
74. Kusumawati I. A great challenge on the reproducibility of therapeutic results of phytopharmaceuticals. *Phytopharmaceuticals: Potential Therapeutic Applications*. 2021 Jun 3:1–8. <https://doi.org/10.1002/9781119682059.ch1>
75. Li C, Li Y, Huang X, Li S, Sangji K, Gu R. Traditional Tibetan medicine: therapeutic potential in lung diseases. *Frontiers in Pharmacology*. 2024 Mar 18;15:1365911. doi:10.3389/fphar.2024.1365911
76. Lim CL, Raju CS, Mahboob T, et al. Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications. *Nanomaterials*. 2022;12(2):238. doi:10.3390/nano12020238
77. Luikham S, Bhattacharyya J. On the traditional medicinal plants and plant-derived natural drugs used by indigenous people of Nagaland, India. *Nat Prod Res*. 2024;39(4):848–63. <https://doi.org/10.1080/14786419.2024.2315594>
78. Macias JP, Castro RI, Esguerra SK, Marin JG, Guzman L, Gutierrez M, Vergara CE, Forero-Doria O. Eugenol supplementation as an additive to improve the thermal stability of *Hedychium coronarium* Koenig essential oil. *The Natural Products Journal*. 2020 Jun 1;10(3):279–85. <https://doi.org/10.2174/2210315509666190417145908>
79. Mancao L, Lumogdang L. Ethno-botanical survey of indigenous herbs and spices in the municipality of Jose Abad Santos, Davao Occidental Philippines. *Journal of Biodiversity and Environmental Sciences (JBES)*. 2023 Jun 16;22(6):199–207. doi:10.2139/ssrn.4922451

80. Manghani K. Quality assurance: Importance of systems and standard operating procedures. Perspectives in clinical research. 2011 Jan 1;2(1):34-7.doi:10.20959/wjpps20243-26758.
81. Mannino G, Occhipinti A, Maffei ME. Quantitative determination of 3-O-acetyl-11-keto- $\beta$ -boswellic acid (AKBA) and other boswellic acids in *Boswellia sacra* Flueck (syn. *B. carteri* Birdw) and *Boswellia serrata* Roxb. *Molecules*. 2016 Oct 6;21(10):1329.doi:10.3390/molecules21101329
82. Marcelino S, Hamdane S, Gaspar PD, Paço A. Sustainable Agricultural Practices for the Production of Medicinal and Aromatic Plants: Evidence and Recommendations. *Sustainability*. 2023;15(19):14095. doi:10.3390/su151914095
83. Metta AM, Kingumahanthi NL, Kalidindi VR, Juturi RK, Boddu V. Scope for harmonisation of herbal medicine regulations. *Int J Pharm Sci Res*. 2021;12(4):2012–20. doi:10.13040/IJPSR.0975-8232.12(4).2012-20
84. Miller WG. Harmonization: Its Time Has Come. *Clin Chem*. 2017;63(7):1184–1186. doi:10.1373/clinchem.2017.274860
85. Moghaddam MS, Kumar PA, Reddy GB, Ghole VS. Effect of Diabecon on sugar-induced lens opacity in organ culture: mechanism of action. *J Ethnopharmacol*. 2005;97(2):397–403. <https://doi.org/10.1016/j.jep.2004.11.032>
86. Mueed A, Shibli S, Al-Quwaie DA, Ashkan MF, Alharbi M, Alanazi H, Binothman N, Aljadani M, Majrashi KA, Huwaikem M, Abourehab MA. Extraction, characterization of polyphenols from certain medicinal plants and evaluation of their antioxidant, antitumor, antidiabetic, antimicrobial properties, and potential use in human nutrition. *Frontiers in Nutrition*. 2023 Jun 21;10:1125106.doi:10.3389/fnut.2023.1125106
87. Mukherjee PK. Phyto-pharmaceuticals, nutraceuticals and their evaluation. Quality control and evaluation of herbal drugs. 2019:707-22.doi:10.1016/B978-0-12-813374-3.00020-X
88. Muyumba NW, Mutombo SC, Sheridan H, Nachtergaeel A, Duez P. Quality control of herbal drugs and preparations: The methods of analysis, their relevance and applications. *Talanta Open*. 2021 Dec 1;4:100070.doi:10.1016/j.talo.2021.100070.